MRD Focus: why measurable residual disease testing is the future
Bruno Paiva et al.
Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
Death from infection: reducing the risk in patients with CLL
Novel revelations in CLL biology with venetoclax/ibrutinib
Using MRD to inform CLL treatment in a clinical trial